Selected research
Industry Research
Canine Tumor Screening Industry Research Report 2026
Market perspective
The global Canine Tumor Screening market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Canine Tumor Screening market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Canine Tumor Screening market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Canine Tumor Screening market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Canine Tumor Screening include PetDx, CYTOGEN, BioChain, Small Door, ANGLE, BioChain Institute Inc. and CANCAN DIAGNOSTICS., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Canine Tumor Screening market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Canine Tumor Screening.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Canine Tumor Screening Market by Company
PetDx
CYTOGEN
BioChain
Small Door
ANGLE
BioChain Institute Inc.
CANCAN DIAGNOSTICS.
Canine Tumor Screening Segment by Type
Cut Biopsy
Needle Biopsy
Canine Tumor Screening Segment by Application
Pet Hospital
Clinic
Canine Tumor Screening Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Canine Tumor Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Canine Tumor Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Canine Tumor Screening.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Canine Tumor Screening companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cut Biopsy
- Needle Biopsy
Applications
- Pet Hospital
- Clinic
Companies covered
- PetDx
- CYTOGEN
- BioChain
- Small Door
- ANGLE
- BioChain Institute Inc.
- CANCAN DIAGNOSTICS.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Canine Tumor Screening by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Cut Biopsy
- 2.2.3 Needle Biopsy
- 2.3 Canine Tumor Screening by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pet Hospital
- 2.3.3 Clinic
- 2.4 Assumptions and Limitations
3 Canine Tumor Screening Breakdown Data by Type
- 3.1 Global Canine Tumor Screening Historic Market Size by Type (2021-2026)
- 3.2 Global Canine Tumor Screening Forecasted Market Size by Type (2027-2032)
4 Canine Tumor Screening Breakdown Data by Application
- 4.1 Global Canine Tumor Screening Historic Market Size by Application (2021-2026)
- 4.2 Global Canine Tumor Screening Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Canine Tumor Screening Market Perspective (2021-2032)
- 5.2 Global Canine Tumor Screening Growth Trends by Region
- 5.2.1 Global Canine Tumor Screening Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Canine Tumor Screening Historic Market Size by Region (2021-2026)
- 5.2.3 Canine Tumor Screening Forecasted Market Size by Region (2027-2032)
- 5.3 Canine Tumor Screening Market Dynamics
- 5.3.1 Canine Tumor Screening Industry Trends
- 5.3.2 Canine Tumor Screening Market Drivers
- 5.3.3 Canine Tumor Screening Market Challenges
- 5.3.4 Canine Tumor Screening Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Canine Tumor Screening Players by Revenue
- 6.1.1 Global Top Canine Tumor Screening Players by Revenue (2021-2026)
- 6.1.2 Global Canine Tumor Screening Revenue Market Share by Players (2021-2026)
- 6.2 Global Canine Tumor Screening Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Canine Tumor Screening Head Office and Area Served
- 6.4 Global Canine Tumor Screening Players, Product Type & Application
- 6.5 Global Canine Tumor Screening Manufacturers Established Date
- 6.6 Global Canine Tumor Screening Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Canine Tumor Screening Market Size (2021-2032)
- 7.2 North America Canine Tumor Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Canine Tumor Screening Market Size by Country (2021-2026)
- 7.4 North America Canine Tumor Screening Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Canine Tumor Screening Market Size (2021-2032)
- 8.2 Europe Canine Tumor Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Canine Tumor Screening Market Size by Country (2021-2026)
- 8.4 Europe Canine Tumor Screening Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Canine Tumor Screening Market Size (2021-2032)
- 9.2 Asia-Pacific Canine Tumor Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Canine Tumor Screening Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Canine Tumor Screening Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Canine Tumor Screening Market Size (2021-2032)
- 10.2 South America Canine Tumor Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Canine Tumor Screening Market Size by Country (2021-2026)
- 10.4 South America Canine Tumor Screening Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Canine Tumor Screening Market Size (2021-2032)
- 11.2 Middle East & Africa Canine Tumor Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Canine Tumor Screening Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Canine Tumor Screening Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 PetDx
- 12.1.1 PetDx Company Information
- 12.1.2 PetDx Business Overview
- 12.1.3 PetDx Revenue in Canine Tumor Screening Business (2021-2026)
- 12.1.4 PetDx Canine Tumor Screening Product Portfolio
- 12.1.5 PetDx Recent Developments
- 12.2 CYTOGEN
- 12.2.1 CYTOGEN Company Information
- 12.2.2 CYTOGEN Business Overview
- 12.2.3 CYTOGEN Revenue in Canine Tumor Screening Business (2021-2026)
- 12.2.4 CYTOGEN Canine Tumor Screening Product Portfolio
- 12.2.5 CYTOGEN Recent Developments
- 12.3 BioChain
- 12.3.1 BioChain Company Information
- 12.3.2 BioChain Business Overview
- 12.3.3 BioChain Revenue in Canine Tumor Screening Business (2021-2026)
- 12.3.4 BioChain Canine Tumor Screening Product Portfolio
- 12.3.5 BioChain Recent Developments
- 12.4 Small Door
- 12.4.1 Small Door Company Information
- 12.4.2 Small Door Business Overview
- 12.4.3 Small Door Revenue in Canine Tumor Screening Business (2021-2026)
- 12.4.4 Small Door Canine Tumor Screening Product Portfolio
- 12.4.5 Small Door Recent Developments
- 12.5 ANGLE
- 12.5.1 ANGLE Company Information
- 12.5.2 ANGLE Business Overview
- 12.5.3 ANGLE Revenue in Canine Tumor Screening Business (2021-2026)
- 12.5.4 ANGLE Canine Tumor Screening Product Portfolio
- 12.5.5 ANGLE Recent Developments
- 12.6 BioChain Institute Inc.
- 12.6.1 BioChain Institute Inc. Company Information
- 12.6.2 BioChain Institute Inc. Business Overview
- 12.6.3 BioChain Institute Inc. Revenue in Canine Tumor Screening Business (2021-2026)
- 12.6.4 BioChain Institute Inc. Canine Tumor Screening Product Portfolio
- 12.6.5 BioChain Institute Inc. Recent Developments
- 12.7 CANCAN DIAGNOSTICS.
- 12.7.1 CANCAN DIAGNOSTICS. Company Information
- 12.7.2 CANCAN DIAGNOSTICS. Business Overview
- 12.7.3 CANCAN DIAGNOSTICS. Revenue in Canine Tumor Screening Business (2021-2026)
- 12.7.4 CANCAN DIAGNOSTICS. Canine Tumor Screening Product Portfolio
- 12.7.5 CANCAN DIAGNOSTICS. Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst